


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. **(Original)** A compound of formula I, or a pharmaceutically acceptable salt thereof,



wherein:

Z^1 is N or CH;

Z^2 and Z^3 are each independently N or CR^7 ;

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , and R^7 are each independently H, R^8 , or R^9 ;

each R^8 is independently a hydrocarbyl group; and

each R^9 is independently halo, NO_2 , alkoxy, CN, CF_3 , SO_3H , $SO_2NR^{10}R^{11}$, SO_2R^{12} , $NR^{13}R^{14}$, $(CH_2)_aCOOR^{15}$, $(CH_2)_bCONR^{16}R^{17}$, $(CH_2)_cCOR^{18}$ or $(CH_2)_dOH$;

a, b, c and d are each independently 0, 1 2 3 or 4;

R^{10-18} are each independently H or alkyl;

provided that when R^1 and R^2 are both H,

Z^1 is CH; or

Z^2 is N; or

Z^1 is CH and Z^2 is N;

and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine.

2. **(Original)** A compound according to claim 1 wherein each R^8 is independently a C_{1-30} hydrocarbyl group, optionally containing up to twelve heteroatoms selected from N, S, and O, and optionally bearing up to six substituents each independently selected from halo, NO_2 , CN, CF_3 , SO_3H , SO_2NH_2 , SO_2Me , OH, NH_2 , COOH, and $CONH_2$.

3. **(Currently Amended)** A compound according to claim 1 ~~or claim 2~~ wherein each R⁸ is independently an alkyl group, an aryl group or a cycloheteroalkyl group.

4. **(Currently Amended)** A compound according to claim 1 ~~or claim 2~~ wherein each R⁹ is independently halo, NO₂, alkoxy, CN, CF₃, SO₃H, SO₂NH₂, SO₂Me, OH, NH₂, (CH₂)_aCOOR¹⁵, (CH₂)_dOH, CONH₂ or COR¹⁸.

5. **(Currently Amended)** A compound according to ~~any preceding~~ claim 1 wherein:

R¹ is H, alkyl, aryl, (CH₂)_aCOOR¹⁵ or OH;
R² is H, (CH₂)_dOH, (CH₂)_aCOOR¹⁵, COR¹⁸ or alkyl;
R³ is halo, H, alkoxy, cycloheteroalkyl, alkyl or OH;
R⁴ is H, NH₂, OH, alkyl, CF₃ or NO₂; and
R⁵ and R⁶ are both H.

6. **(Currently Amended)** A compound according to ~~any preceding~~ claim 1 wherein:

R¹ is H, Me, Ph, CH₂COOMe or OH;
R² is H, (CH₂)₂OH, COOEt, COMe or Me;
R³ is Cl, H, OMe, N-morpholinyl, N-pyrrolidinyl, Me or OH;
R⁴ is H, NH₂, OH, Me, CF₃ or NO₂; and
R⁵ and R⁶ are both H.

7. **(Original)** A compound according to claim 1 wherein Z¹ is CH and Z² and Z³ are each independently N or CR⁷.

8. **(Original)** A compound according to claim 7 wherein Z² and Z³ are each independently CR⁷.

9. **(Currently Amended)** A compound according to claim 7 ~~or claim 8~~ wherein:

R¹ is alkyl or OH;
R² is alkyl or COR¹⁸;
R³ is OH or halo; and
Z² and Z³ are both CH.

10. **(Original)** A compound according to claim 9 wherein R¹ is Me or OH, R² is COMe or Me, and R³ is OH or Cl.

11. **(Original)** A compound according to claim 1 wherein Z^1 is N and Z^2 and Z^3 are each independently N or CR^7 .

12. **(Original)** A compound according to claim 11 wherein Z^2 and Z^3 are each independently CR^7 .

13. **(Original)** A compound according to claim 12 wherein:

R^1 is alkyl, aryl, OH or $(CH_2)_aCOOR^{15}$;

R^2 is COR^{18} , H, $COOR^{15}$ or alkyl;

R^3 is halo, H, OH, alkyl or morpholino;

R^4 is H, NH_2 , OH, CF_3 or NO_2 ; and

Z^2 and Z^3 are both CH.

14. **(Original)** A compound according to claim 13 wherein:

R^1 is Me, Ph, OH or CH_2COOMe ;

R^2 is $COMe$, H, $COOEt$ or Me; and

R^3 is halo, H, OH, alkyl or morpholino.

15. **(Original)** A compound according to claim 11 wherein Z^2 is N and Z^3 is CR^7 .

16. **(Original)** A compound according to claim 15 wherein:

R^1 is H, OH or alkyl;

R^2 is H, $(CH_2)_dOH$, alkyl, $(CH_2)_aCOOR^{15}$, COR^{18} ;

R^3 is halo, alkoxy or heterocycloalkyl;

R^4 is H or alkyl; and

Z^3 is CH.

17. **(Original)** A compound according to claim 16 wherein:

R^1 is H, OH or Me;

R^2 is H, $(CH_2)_2OH$, Me, $COOEt$, $COMe$;

R^3 is halo, OMe or N-pyrrolidinyl;

R^4 is H or Me; and

Z^3 is CH.

18. **(Original)** A compound according to claim 1 which is selected from the following:

1-{2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-5-yl}-ethanone

(4-Chloro-phenyl)-[4-(4-methyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
(4-Chloro-phenyl)-[4-(4-phenyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazole-5-carboxylic acid
ethyl ester
{2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-thiazol-4-yl}-acetic acid methyl ester
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid
ethyl ester
N-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-benzene-1,3-diamine
3-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(3-trifluoromethyl-phenyl)-amine
(4-Chloro-3-trifluoromethyl-phenyl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-
amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine
(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
1-{2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-methyl-thiazol-5-yl}-
ethanone
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(6-methoxy-pyridin-3-yl)-amine
(6-Chloro-pyridin-3-yl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(4-morpholin-4-yl-phenyl)-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(4-methyl-3-nitro-phenyl)-amine
4-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol
(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic
acid ethyl ester
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol
(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.

19. **(Original)** A compound according to claim 1 which is selected from the following:

2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid
ethyl ester;
N-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-benzene-1,3-diamine
3-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(3-trifluoromethyl-phenyl)-amine

(4-Chloro-3-trifluoromethyl-phenyl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine

(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(6-methoxy-pyridin-3-yl)-amine

2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol

(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol

(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.

20. **(Original)** A compound according to claim 1 which is selected from the following:

2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester;

(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine; and

(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol

(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol

(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

21. **(Original)** A compound according to claim 1 which is (6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.


22. **(Currently Amended)** A pharmaceutical composition comprising a compound according to ~~any preceding~~ claim 1 admixed with a pharmaceutically acceptable diluent, excipient or carrier.

Claims 23-41 **(Canceled)**.


42. **(Currently Amended)** Use of a compound according to ~~any one of~~ claims 1 to 21 in an assay for identifying further candidate compounds capable of inhibiting one or more of a cyclin dependent kinase, aurora kinase, GSK and a PLK enzyme.

43. **(Currently Amended)** Use according to claim ~~42~~38 wherein said assay is a competitive binding assay.

44. **(Original)** A process for preparing a compound of formula I as defined in claim 1, said process comprising reacting a compound of formula 9 with a compound of formula 10 to form a compound of formula I, wherein R¹⁻⁶ are as defined in claim 1



45. **(Original)** A process for preparing a compound of formula I as defined in claim 1, said process comprising reacting a compound of formula 15 with a compound of formula 3 to form a compound of formula I, wherein R¹⁻⁶ are as defined in claim 1



46. **(New)** A method of treating a proliferative disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the proliferative disorder is treated.

47. **(New)** The method of claim 46, wherein the proliferative disorder is cancer or leukemia.

48. **(New)** The method of claim 46, wherein the proliferative disorder is glomerulonephritis, rheumatoid arthritis, psoriasis or chronic obstructive pulmonary disorder.

49. **(New)** A method of treating a viral disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the viral disorder is treated.

50. **(New)** The method according to claim 49, wherein the viral disorder is selected from human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus type 1 (HIV-1), and varicella zoster virus (VZV).

51. **(New)** A method of treating a CNS disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the CNS disorder is treated.

52. **(New)** The method according to claim 51, wherein the CNS disorder is Alzheimer's disease or bipolar disorder.

53. **(New)** A method of treating alopecia, said method comprising administering to a subject in need thereof, a compound of claim 1, such that alopecia is treated.

54. **(New)** A method of treating a stroke, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the stroke is treated.

55. **(New)** The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit at least one PLK enzyme.

56. **(New)** The method according to claim 55, wherein the PLK enzyme is PLK1.

57. **(New)** The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit at least one CDK enzyme.

58. **(New)** The method according to claim 57, wherein the CDK enzyme is CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 and/or CDK9.

59. **(New)** The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit aurora kinase.

60. **(New)** A method of treating diabetes, said method comprising administering to a subject in need thereof, a compound of claim 1, such that diabetes is treated.

61. **(New)** The method according to claim 60, wherein the diabetes is non-insulin-dependent diabetes or Type II diabetes.

62. **(New)** The method according to claim 60, wherein the compound is administered in an amount sufficient to inhibit GSK.

63. **(New)** The method according to claim 62, wherein the compound is administered in an amount sufficient to inhibit GSK3 β .

64. **(New)** A method of treating an inflammatory disease, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the inflammatory disease is treated.

65. **(New)** A method of treating an infectious disease, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the infectious disease is treated.